Skip to content
Inteligencia IAMay 15, 2026Inteligencia IA
Artigo

TuHURA Biosciences, an immuno-oncology company, released Q1 2026 financial results.

The company is developing novel therapies to overcome resistance to cancer immunotherapy.

Editorial Data Cube AIFonte: PR Newswire
01

Brief da fonte

TuHURA Biosciences, an immuno-oncology company, released Q1 2026 financial results. The company is developing novel therapies to overcome resistance to cancer immunotherapy.